| HOME >> BIOLOGY >> TECHNOLOGY |
Three Months Ended Twelve Months Ended
December 31, December 31,
2007 2006 2007 2006
Net revenues $627,335 $621,162 $2,496,651 $1,979,244
Cost of sales (excludes
amortization, presented
below) 373,178 409,973 1,504,756 1,233,483
Gross profit 254,157 211,189 991,895 745,761
Operating expenses:
Research and development 35,825 40,614 144,793 131,023
Selling, general and
administrative 108,284 103,069 421,151 305,060
Amortization 44,158 42,117 176,409 163,710
In-process research and
development - 497,800 - 497,800
Net loss (gain) on asset
sales and impairments - 3,283 (6,118) 70,264
Total operating expenses 188,267 686,883 736,235 1,167,857
Operating income (loss) 65,890 (475,694) 255,660 (422,096)
Non-operating (expense)
income, net:
Loss on early
extinguishment of debt (1,143) - (5,553) (525)
Interest income 2,190 5,652 8,886 28,418
Interest expense (8,997) (11,645) (44,473) (22,082)
Other income 1,878 485 9,764 5,336
Total non-operating
(expense) income, net (6,072) (5,508) (31,376) 11,147
Income (loss) before income
taxes 59,818 (481,202) 224,284 (410,949)
Provision for income taxes 21,415 7,759 83,254 34,056
Net income (loss) $38,403 $(488,9
'/>"/>
| SOURCE Watson Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |